Manual of Catholic Medical Ethics – Chapter IV

on-line edition as of 2023 edited by Willem J. cardinal Eijk, MD PhD STL, Lambert J.M. Hendriks, PhD STD and prof FransJ. van Ittersum, MD PhD MSc

Ⓒ Katholieke Stichting Medische Ethiek 2014 - 2024

IV.3.4 Xenotransplantation

F.J. van Ittersum, W.J. Eijk

3.4.5 Patentability

Without doubt, private companies have invested much money and energy in the development of xenotransplantation. The application for a patent is therefore a logical step for such companies. Patents, however, lead to higher costs for the consumers, in comparison to non-patented products. Even though there is no moral objection to patents, as such, it is important to guarantee that the recipients will have equal access to healthcare, without any form of discrimination and impediments based on higher costs [23Pontifical Academy for Life. Prospects for xenotransplantation scientific aspects and ethical considerations. Vatican City 2001.].

image_pdfimage_print